228 related articles for article (PubMed ID: 26059395)
21. Glucocorticoid-induced tumor necrosis factor receptor expression in patients with cervical human papillomavirus infection.
Padovani CT; Bonin CM; Tozetti IA; Ferreira AM; Fernandes CE; Costa IP
Rev Soc Bras Med Trop; 2013; 46(3):288-92. PubMed ID: 23856878
[TBL] [Abstract][Full Text] [Related]
22. Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expression of interleukin-32 controls the expression of the human papillomavirus oncogene.
Lee S; Kim JH; Kim H; Kang JW; Kim SH; Yang Y; Kim J; Park J; Park S; Hong J; Yoon DY
Immunology; 2011 Mar; 132(3):410-20. PubMed ID: 21208204
[TBL] [Abstract][Full Text] [Related]
23. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome.
de Gruijl TD; Bontkes HJ; Walboomers JM; Coursaget P; Stukart MJ; Dupuy C; Kueter E; Verheijen RH; Helmerhorst TJ; Duggan-Keen MF; Stern PL; Meijer CJ; Scheper RJ
J Gen Virol; 1999 Feb; 80 ( Pt 2)():399-408. PubMed ID: 10073700
[TBL] [Abstract][Full Text] [Related]
24. [Association between high risk human papillomavirus DNA load and cervical lesions in different infection status].
Li TY; Wu ZN; Jiang MY; Cui JF; Liu B; Chen F; Chen W
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):475-480. PubMed ID: 29936777
[No Abstract] [Full Text] [Related]
25. Spotlight on AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®).
McKeage K; Romanowski B
BioDrugs; 2011 Aug; 25(4):265-9. PubMed ID: 21815703
[TBL] [Abstract][Full Text] [Related]
26. Surgery followed by persistence of high-grade squamous intraepithelial lesions is associated with the induction of a dysfunctional HPV16-specific T-cell response.
de Vos van Steenwijk PJ; Piersma SJ; Welters MJ; van der Hulst JM; Fleuren G; Hellebrekers BW; Kenter GG; van der Burg SH
Clin Cancer Res; 2008 Nov; 14(22):7188-95. PubMed ID: 19010835
[TBL] [Abstract][Full Text] [Related]
27. HPV16 tumor associated macrophages suppress antitumor T cell responses.
Lepique AP; Daghastanli KR; Cuccovia IM; Villa LL
Clin Cancer Res; 2009 Jul; 15(13):4391-400. PubMed ID: 19549768
[TBL] [Abstract][Full Text] [Related]
28. Nocardia Rubra Cell Wall Skeleton Up-Regulates T Cell Subsets and Inhibits PD-1/PD-L1 Pathway to Promote Local Immune Status of Patients With High-Risk Human Papillomavirus Infection and Cervical Intraepithelial Neoplasia.
Chen W; Zhang Y; Zhao C; Shao S; Zhang Y; Li X; Bai X; Guo Q; Liu Q; Tang J; Zhang L
Front Immunol; 2020; 11():612547. PubMed ID: 33552075
[TBL] [Abstract][Full Text] [Related]
29. CD4+ T cells against human papillomavirus-18 E7 in patients with high-grade cervical lesions associate with the absence of the virus in the cervix.
Seresini S; Origoni M; Caputo L; Lillo F; Longhi R; Vantini S; Paganoni AM; Protti MP
Immunology; 2010 Sep; 131(1):89-98. PubMed ID: 20545782
[TBL] [Abstract][Full Text] [Related]
30. Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease.
Hildesheim A; Schiffman MH; Tsukui T; Swanson CA; Lucci J; Scott DR; Glass AG; Rush BB; Lorincz AT; Corrigan A; Burk RD; Helgesen K; Houghten RA; Sherman ME; Kurman RJ; Berzofsky JA; Kramer TR
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):807-13. PubMed ID: 9332763
[TBL] [Abstract][Full Text] [Related]
31. Association of Human Papillomavirus Genotype 16 Viral Variant and Viral Load with Cervical High-grade Intraepithelial Lesions.
Álvarez-Paredes L; Santibañez M; Galiana A; Rodríguez Díaz JC; Parás-Bravo P; Andrada-Becerra ME; Ruiz García MM; Rodríguez-Ingelmo JM; Portilla-Sogorb J; Paz-Zulueta M
Cancer Prev Res (Phila); 2019 Aug; 12(8):547-556. PubMed ID: 31208965
[TBL] [Abstract][Full Text] [Related]
32. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.
Castellsagué X; Schneider A; Kaufmann AM; Bosch FX
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S15-23. PubMed ID: 19819540
[TBL] [Abstract][Full Text] [Related]
33. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
34. Binding of human papillomavirus type 16 to heparan sulfate is inhibited by mucosal antibodies from patients with low-grade squamous intraepithelial lesions but not from cervical cancer patients.
Lopez TV; Cancio C; Cruz-Talonia F; Ruiz B; Sapp M; Rocha-Zavaleta L
FEMS Immunol Med Microbiol; 2008 Nov; 54(2):167-76. PubMed ID: 19049640
[TBL] [Abstract][Full Text] [Related]
35. Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection.
Kobayashi A; Greenblatt RM; Anastos K; Minkoff H; Massad LS; Young M; Levine AM; Darragh TM; Weinberg V; Smith-McCune KK
Cancer Res; 2004 Sep; 64(18):6766-74. PubMed ID: 15374995
[TBL] [Abstract][Full Text] [Related]
36. Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.
Castellsagué X; Naud P; Chow SN; Wheeler CM; Germar MJ; Lehtinen M; Paavonen J; Jaisamrarn U; Garland SM; Salmerón J; Apter D; Kitchener H; Teixeira JC; Skinner SR; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; de Carvalho NS; Peters K; Tjalma WA; Safaeian M; Raillard A; Descamps D; Struyf F; Dubin G; Rosillon D; Baril L
J Infect Dis; 2014 Aug; 210(4):517-34. PubMed ID: 24610876
[TBL] [Abstract][Full Text] [Related]
37. Immunosuppressive cytokine Interleukin-10 (IL-10) is up-regulated in high-grade CIN but not associated with high-risk human papillomavirus (HPV) at baseline, outcomes of HR-HPV infections or incident CIN in the LAMS cohort.
Syrjänen S; Naud P; Sarian L; Derchain S; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Hammes LS; Costa S; Syrjänen K
Virchows Arch; 2009 Dec; 455(6):505-15. PubMed ID: 19908064
[TBL] [Abstract][Full Text] [Related]
38. Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology.
Tsukui T; Hildesheim A; Schiffman MH; Lucci J; Contois D; Lawler P; Rush BB; Lorincz AT; Corrigan A; Burk RD; Qu W; Marshall MA; Mann D; Carrington M; Clerici M; Shearer GM; Carbone DP; Scott DR; Houghten RA; Berzofsky JA
Cancer Res; 1996 Sep; 56(17):3967-74. PubMed ID: 8752165
[TBL] [Abstract][Full Text] [Related]
39. Correlates of cervical mucosal antibodies to human papillomavirus 16: results from a case control study.
Bierl C; Karem K; Poon AC; Swan D; Tortolero-Luna G; Follen M; Wideroff L; Unger ER; Reeves WC
Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S262-8. PubMed ID: 16229879
[TBL] [Abstract][Full Text] [Related]
40. Presence of multiple human papillomavirus types in cervical samples from HIV-infected women.
Levi JE; Fernandes S; Tateno AF; Motta E; Lima LP; Eluf-Neto J; Pannuti CS
Gynecol Oncol; 2004 Jan; 92(1):225-31. PubMed ID: 14751163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
